BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19465447)

  • 1. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
    Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
    Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
    J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Di Sapio A; Capobianco M; Bertolotto A
    J Neuroimmunol; 2005 Jan; 158(1-2):195-203. PubMed ID: 15589054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
    Pachner AR; Dail D; Pak E; Narayan K
    J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
    Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
    Hegen H; Guger M; Harrer A; Hoelzl M; Kraus J; Skrobal A; Schautzer F; Schmidegg S; Schocke M; Deisenhammer F
    Mult Scler Relat Disord; 2014 Mar; 3(2):220-6. PubMed ID: 25878009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
    Vallittu AM; Salmi AA; Erälinna JP;
    Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.